Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unbelievable...........I guess they are holding true to there business plan, only the rich can afford the juice. Nobody gets a piece. To bad........So sad
Gap Filled......
I absolutely agree Lumdus.
This is business, and has nothing to do with the integrity and accomplishments of Dr.Sidransky and Co.
The nature of this business is very competitive, cut throat and very expensive.
We are all on the same team. Quite Frankly I understand why they are doing it, and it makes total sense. This is a business decision, but it has to be disclosed and I believe it will be. In the business world, timing is everything.
It's just a stock, and all equities have risk.
The way I read it, is that every drug contract, present and future, will be passed on to the new Company. with the parent having a minority stake in the pie. But I agree it is a little confusing given the translation.
Guy Malchi will run the new Company and if I read and understood it correctly, is now done with the Parent Company.
When did this take place??
As I stated before, the lack of disclosure on this very important development is very, very concerning to me.
Once again, who are the shareholders? What Percentage does Champions have in this new company?
Very confusing........I don't like it as it stands right now. There are too many unknowns, which shouldn't be the case.
Hi Fred, I couldn't find the article in English either. But I can't think, or find any other reason they would spin this off, with the parent company (Champions) having a minority stake. Especially with Battery Ventures and more importantly Scott Tobin,(who heads the Israeli Office for Battery)on board with a substantial investment in the parent company.
Champions is protecting this Asset. If Champions get bought out, the buyer gets a minority stake in the new company. So essentially they are buying the TOS business and Personalized Oncology business, yet Sidransky and whom ever else is involved in the spinoff, retains a majority stake in the drug. Where the Real Money is.
It could simply be an Incubator Company as well. But this drug is going into Clinical Trials. As I said in a previous post, one of the biggest Pharma's in the world has a drug already on the market to target this specific cancer. If this drug comes to fruition, it will be better, much better.
Maybe I'm reading to much into this, but with the lack of disclosure, something is up.
It seems this may be an anti takeover strategy by the company, Hence the reason for the minority stake in the spinoff Fred. Anyway you look at it, it greatly diminishes the value of Champions Inc. when you look at it from the outside. Having said that, there are so many unanswered questions.
They will still be using the platform for their TOS services, but anybody who follows Drug and Pharma knows that New, Novel Blockbuster Drugs is where the real money is.
It concerns me that the company did this privately without any disclosure at all. Is Teva Involved with the Spin? Who are the Investors in the new Co? If Champions has a Private stake in the company, they should be disclosing it.
Is this going to be an R and D company? We all know R & D can Literally Kill small Biotech's, so this move could make Champions look leaner to new investors. Another Question that needs to be answered.
I personally think, and it is only my opinion of course, that this is an asset retainment strategy. to avoid any takeovers. This New Drug has the potential to compete with another big, HUGE, Pharma.
Disclosure is a must, this company is so well structured and managed, this is the only reason I have kept my investment in Champions.
LOL, the writing is on the wall now! Unbelievable.
What do you think Fred?? Are you still around?
Hello Lumdus,
They are creating another subsidiary? Guy is already the head of the U.K based subsidiary, which was created a couple of years ago.
Do you have a link to that news?
Thanks
LOL...That's funny!!
Sound Familiar?
http://www.secinfo.com/d12Ddz.t9m.htm#1stPage
Link Resources Inc.
We are in the business of mineral exploration. On April 1, 2008, we entered in a Mineral Lease Agreement whereby we leased from Timberwolf Minerals, LTD a total of two (2) unpatented lode mining claims in the State of Nevada which we refer to as the Goldbanks East Prospect. These mineral claims are located in Section 20, Township 30 North, Range 39 East, Mt. Diablo Baseline & Meridian, Pershing County, Nevada, USA, owned by Timberwolf Minerals LTD.
According to the lease Link has agreed to pay Timberwolf Minerals, LTD minimum royalty payments which shall be paid in advance. Link paid the sum of $5,000 upon execution of this lease. Link has agreed to pay $5,000 on or before the first anniversary of the lease, $10,000 on or before the second and third anniversary of the lease, $25,000 on or before the fourth anniversary of the lease and each annual payment after that shall be $75,000 plus an annual increase or decrease equivalent to the rate of inflation designated by the Consumer’s Price Index for that year with execution year as base year.. Link will pay Timberwolf Minerals, LTD a royalty of 3.5% of the Net Returns from all ores, minerals, concentrates, or other products mined and removed from the property and sold or processed by Link, quarterly. The term of this lease is for twenty (20) years, renewable for an additional twenty (20) years so long as conditions of the lease are met.
Our plan of operations is to conduct mineral exploration activities on the Goldbanks East Prospect in order to assess whether these claims possess commercially exploitable mineral deposits. (Commercially exploitable mineral deposits are deposits which are suitably adequate or prepared for productive use of a natural accumulation of minerals or ores). Our exploration program is designed to explore for commercially viable deposits of gold, silver, copper or any other valuable minerals. (Commercially viable deposits are deposits which are suitably adequate or prepared for productive use of an economically workable natural accumulation of minerals or ores). We have not, nor has any predecessor, identified any commercially exploitable reserves of these minerals on our mineral claims. (A reserve is an estimate within specified accuracy limits of the valuable metal or mineral content of known deposits that may be produced under current economic conditions and with present technology). We are an exploration stage company and there is no assurance that a commercially viable mineral deposit exists on our mineral claims.
After acquiring a lease on the Goldbanks East Prospect, we retained the services of Robert Thomas, a Professional Geologist. Mr. Thomas prepared a geologic report for us on the mineral exploration potential of the claims. Mr. Thomas has no direct or indirect interest and does not expect to receive an interest in any of the Goldbanks East Prospect claims. Included in this report is a recommended exploration program which consists of mapping, sampling, staking additional claims and drilling. The recommendations of Mr. Thomas are further explained in the “Description of Business” section.
?
?
?
?
3
?
?
Table of Contents
At this time we are uncertain of the extent of mineral exploration we will conduct before concluding that there are, or are not, commercially viable minerals on our claims. Further phases beyond the current exploration program will be dependent upon numerous factors such as Mr. Thomas’ recommendations based upon ongoing exploration program results and our available funds.
We have not earned any revenues to date. We do not anticipate earning revenues until such time as we have entered into commercial production of our mineral properties. We are presently in the exploration stage of our business and we can provide no assurance that we will discover commercially exploitable levels of mineral resources on our property, or if such resources are discovered, that we will enter into commercial production of our mineral property.
As of May 31, 2008, we had $47,768 cash on hand and no liabilities. Accordingly our working capital position as of May 31, 2008 was $47,768. Since our inception through May 31, 2008, we have incurred a net loss of $6,232. We attribute our net loss to having no revenues to offset our expenses and the professional fees related to the creation and operation of our business.
Our fiscal year ended is May 31.
We were incorporated on January 9, 2008 under the laws of the State of Nevada. Our principal offices are located at 392 Acadia Drive, SE, Calgary, Alberta, Canada. Our telephone number is (403) 230-0945.
Yep.... Here you go.....
http://www.secinfo.com/d12Ddz.t9m.htm
Check out Mineral Lease agreement
http://www.businesswire.com/news/home/20100105006971/en/Link-Resources-Completes-Share-Exchange-Transaction-12
Cheers
Beaner
LOL! Have you done any DD on Link Resources? Check out their 8k from last year.
CAMLD.....sounds painful!
Another Positive Sign......
A former Executive Officer takes 8400 shares of common stock, instead of cash for severance.
No Volume = Iliquidity.............By Accredited I meant people with serious assets willing to invest in the open market..........It's not all bad though, This stock is based on pure fundamentals, not speculation, hence the stock price.
Regards,
Beaner
Fred, this is not high volume. Nobody that is accredited will invest to become illiquid, that is a fact. keep touting on management, because it is needed.
Regards
Beaner
With the Name change, don't be surprised to see a ticker change as well.
I don't know how long you have had your shares, but doubling your money is a pretty good investment.
Here you go Fred.....New 8k out
Entry into a Material Definitive Agreement, Financial Statements an
Item 1.01. Entry into a Material Definitive Agreement.
On March 24, 2011, Champions Biotechnology, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") with Battery Ventures IX, L.P. and Battery Investment Partners IX, LLC (collectively, "Battery"), Harris & Harris Group, Inc., Perceptive Life Sciences Master Fund Ltd., Porter Partners, L.P., EDJ Limited, Northwood Capital Partners, LP, The Oliver D. Curme Children's Trust - 1977, Richard L. Sandor Revocable Trust, Steve Geller, Joel Ackerman, Chief Executive Officer and a director of the Company, Dr. Ronnie Morris, President and a director of the Company, and Bernard Kaminetsky (collectively, the "Investors"), for the sale to the Investors of an aggregate 12,533,333 shares of the Company's Common Stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $0.75 per share, or an aggregate of $9,400,000. As part of the purchase, certain of the Investors received warrants to purchase an aggregate 1,010,000 shares of Common Stock at $0.90 per share (the "Warrants"). The Warrants expire five years after the closing date. Closing is expected to take place within 15 days.
The Agreement contains certain anti-dilution protections for the Investors and certain registration rights with respect to the shares of Common Stock to be issued to the Investors. Furthermore, Investors will have the right to require the Company to repurchase the purchased shares (the "Put Option") for cash for $0.75 upon a change of control or sale of substantially all of the company's assets. The Put Option will terminate upon the achievement of certain financial milestones.
Pursuant to the terms of the Agreement, the Company agreed to present one nominee nominated by Battery to become a member of the Company's Board of Directors either through an action by written consent or through the vote of the Company's stockholders at the next meeting of the Company's stockholders; provided, however, that the Company will not be obligated to present the Battery nominee in the event that Battery has sold greater than or equal to twenty-five percent (25%) of the shares of Common Stock it purchases pursuant to the Agreement.
The shares of Common Stock to be sold pursuant to the Agreement will be sold to accredited investors only in a private placement in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933 and Regulation D promulgated thereunder.
The foregoing description is qualified in its entirety by the terms of the Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference. The Company intends to use up to $1.4 million of the proceeds from the sale to purchase outstanding shares of the Company's Common Stock in one or more private transactions at a discount to the $0.75 purchase price of this financing. The balance of the proceeds will be used for general corporate purposes. The Company intends to issue a press release describing the transaction following the closing.
Fred is that you buying all those shares?
Fred I couldn't agree with you more,this wasn't a shot at your integrity, however sometimes Timing is everything.
With this Company being essentially booted to the pink sheets by means out of their control, there is little to no market right now.
As for a promotion to the big board, we all know how fast this can happen with high growth/margin sectors.
Yes Fred that's a great idea...we could call it "Pump Inc". Relax and read Benz's quotation.....the future is where it's at!!
Well, if they are trying to stay under the radar, then they are doing a great job.
I agree Fred, something is not right. Let's see what happens when the Name change and new charter is put into place. That should be next week, if not sooner.
Yep read the 8k too Fred. It was released after hours, so look for the PR in the morning. 1.3 Million Initation, with a potential of 27 Million if certain milestones are met. Cephalon is a huge Nasdaq100 company.
I can't figure out why they are being quoted on the Pink Sheets though.
Never Mind Fred, I found the documentation, Interesting.........
I wasn't aware of it either Fred, there has been no disclosure on it. Yahoo has them listed as a Pink Sheet stock, last day of trading as an Otcbb stock was Feb.22nd. Could it be from the resignation of the CFO? I wasn't aware that they are changing there name either.....Where and when did you receive this information?
Regards
Beaner
What's you take on the move to the Pink Sheets......hardly a positive step.
Dr Ronnie Morris.....MDVIP
is a national network of physicians who practice proactive, preventive and personalized healthcare, not just the detection and treatment of disease. The national network consists of 376 physicians and over 120,000 patients in 28 states and Washington, D.C. Each physician cares for up to 600 patients rather than the average 2500 patients in a traditional primary care practice. Patients pay an annual membership fee of up to $1800 per year, which includes a comprehensive physical examination and a follow-up wellness plan as well as medical records in CD-ROM format and personalized web sites for each patient. Patients may also be seen for illness as needed. The benefits of a smaller practice are same or next day appointments that start on time as well as unhurried visits and physician availability, 24 hours a day, 7 days a week and enhanced coordination of specialty care.
MDVIP was founded in 2000, and is headquartered in Boca Raton, Florida. Procter & Gamble purchased a share of the company in January 2007, and acquired the company in December 2009.
OMG!!!!! What do you you think guys? Do you think this thing could run???????
Pathetic.....
Just and honest question...why would you disclose your holdings on a public chat board..........
If you think this is a play......then good luck to you.....
Are you that bored? Do a little DD....trust me it is out there.
Regards,
Beaner
Sometimes you just have to let these things play out.......
DW did not get rid of this shell for 8k......Patience is key
In my opinion this shell is a hedge.....
Pretty tough to do when Biogen owns the World Wide Rights rights......... ex-Us to Ampyra.
Ichan seeks to elect Three more board members to Biogen Idec.......
http://dealbook.blogs.nytimes.com/2010/01/29/biogen-confirms-icahns-bid-for-3-board-seats/?partner=yahoofinance
Biogen Idec confirmed on Thursday it has received notice from Carl C. Icahn that he intends to nominate three people to its board as he seeks to expand his influence at one of the world’s biggest biotech companies.
Biogen, the Cambridge, Mass., company that makes the multiple sclerosis drugs Avonex and Tysabri, said it will evaluate the nominees and the proposal and make a recommendation “in the best interests of all shareholders,” Reuters reported.
Two of Mr. Icahn’s three nominees — Thomas Deuel and Eric Rowinsky — were part of the Icahn team that helped engineer the sale of biotechnology company ImClone Systems, which was sold to Eli Lilly & Company for $6.5 billion following a bitter proxy battle with the billionaire investor.
Alexander Denner, managing director at Icahn Partners, who headed the ImClone team, was elected to Biogen’s board last year, along with Richard Mulligan, a professor of genetics at the Harvard Medical School and a former member of ImClone’s Scientific Advisory Committee.
Mr. Icahn’s third nominee is Richard Young, a professor of biology at the Massachusetts Institute of Technology, who was on Mr. Icahn’s slate of nominees to Biogen’s board last year but was not elected.
“I see this as Icahn’s deliberate intention to take control of the board,” one portfolio manager, who owns 244,000 Biogen shares but asked to remain anonymous for compliance reasons, told Reuters. “He’s taken a page out of the book of ImClone.”
Four seats on the 12-member board are up for election. The company’s chief executive, James Mullen, is set to retire and will not stand. Neither will Bruce Ross, the company’s former chairman. The Biogen incumbents up for re-election are Brian Posner, previously the chief executive of ClearBridge Advisors, and Nancy Leaming, the retired chief of Tufts Health Plan.
Mr. Posner was part of Icahn’s slate of nominees to the board of Yahoo in 2008.
Icahn Partners and affiliates reported owning 16.1 million shares of Biogen, or 5.56 percent of the outstanding shares.
Biogen said the proxy materials also include a proposal to amend the company’s bylaws to fix the number of directors at 12.
Biogen’s shares were down 1.7 percent, to $52.66, in early afternoon trading on Nasdaq, amid broad losses for stocks.
There She Blows!
Chief Medical Officer/Consultant
Eric K. Rowinsky, M.D - Former Executive Vice President and Chief Medical Officer of Imclone Systems has joined Champions...........
received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996 to 2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio where he held the SBC Endowed Chair for Early Drug Development and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996 to 2006. From 2005 to 2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs at ImClone Systems. From 2007 to 2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. He is also an Adjuvant Professor of Medicine at New York University School of Medicine and currently serves as a scientific advisor to ImClone Systems and other pharmaceutical and biotechnology companies, with a focus on cancer therapeutic development. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on U01 anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies including a wide variety of cytotoxic and targeted anticancer therapeutics.
Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 300 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI.
Auto has been there for a while now....one hell of a spread eh!!
This company is a little too small for Icahn right now Fred.
Earlier on this year, Sidransky, who is a member of the Icahn Group was one of five members selected by Icahn himself, to take a seat on the BiogenIdec board. He didn't get voted in, but their business relationship is evident.......
Tough to pin point....but they have raised 2.1 million with just three investors so far....Minimum investment is 25000.
Don't know....but they are looking to raise 10 million....and have raised 2.1 million already.